dc.contributor.author | Eroglu, L | |
dc.contributor.author | Caglayan, B | |
dc.contributor.author | Tuna, R | |
dc.date.accessioned | 2021-03-06T10:23:10Z | |
dc.date.available | 2021-03-06T10:23:10Z | |
dc.date.issued | 1996 | |
dc.identifier.citation | Eroglu L., Tuna R., Caglayan B., "Effects of nifedipine and Bay K 8644 on the R-PIA and caffeine-induced changes in the locomotor activity of rats", PHARMACOLOGICAL RESEARCH, cilt.33, ss.141-144, 1996 | |
dc.identifier.issn | 1043-6618 | |
dc.identifier.other | av_ea16af99-e6c9-440d-9410-fb9c8710a694 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/153772 | |
dc.identifier.uri | https://doi.org/10.1006/phrs.1996.0021 | |
dc.description.abstract | Possible interaction between adenosine and L type Ca2+ channel in the locomotor activity of rats was investigated, R-PIA (0.05 mg kg(-1)), an adenosine analogue, (20 mg kg(-1)), an adenosine receptor antagonist, significantly decreased locomotor activity, respectively. Ca2+ channel blocker nifedipine (5 mg kg(-1)) and the channel activator Bay K 8644 (0.5 mg kg(-1)) did not alter the locomotor activity. However, both drugs significantly potentiated the inhibitory effect of R-PIA on the locomotor activity. Additionally, caffeine induced increase in the locomotor activity was significantly blocked by nifedipine and Bay K 8644, This interaction might be due to the inhibitory effects of nifedipine and Bay K 8644 on the uptake of adenosine by rat brain. (C) 1996 The Italian Pharmacological Society | |
dc.language.iso | eng | |
dc.subject | Eczacılık | |
dc.subject | Temel Bilimler | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.title | Effects of nifedipine and Bay K 8644 on the R-PIA and caffeine-induced changes in the locomotor activity of rats | |
dc.type | Makale | |
dc.relation.journal | PHARMACOLOGICAL RESEARCH | |
dc.contributor.department | , , | |
dc.identifier.volume | 33 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 141 | |
dc.identifier.endpage | 144 | |
dc.contributor.firstauthorID | 117229 | |